
Several states had objected to the higher prices being charged from them and private hospitals by the vaccine makers

Majority of the Indian twitter users have expressed their anger on social media over variation in the costs of vaccine set for people.

"We would like to state that more than 50% of our capacities have been reserved for central government supplies," said Krishna M Ella, Bharat Biotec

While the Indian vaccine is cheaper than the foreign makes, it is up to the state governments to dig into their coffers and offer the vaccine for free

Bharat Biotech's Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the globe

Bharat Biotech presented amendments to the subject expert committee of DCGI in the approved Phase 2 clinical trial protocol for administration of boos

India is at an advantageous position as two companies are producing the vaccine and the government should extend all help to increase production

Covaxin has now been granted the restricted emergency use authorisation

The court said the two companies which have developed the vaccines (Covishield and Covaxin) have more capacity but it seems that it is not being explo

After the Phase 3 data is submitted, India can expect an increase in the current rate of the immunisation programme.